As car­dio R&D shrinks in size, a new study high­lights some se­ri­ous pit­falls – and a pos­i­tive shift

In biotech cir­cles, it’s be­come an ar­ti­cle of faith that can­cer of­fers some of the best prospects in new drug de­vel­op­ment. Car­di­ol­o­gy, mean­while, looks …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.